Danaher Corporation (NYSE:DHR – Free Report) – Analysts at Leerink Partnrs decreased their Q1 2026 earnings per share estimates for Danaher in a research report issued on Monday, October 13th. Leerink Partnrs analyst P. Souda now expects that the conglomerate will post earnings of $2.12 per share for the quarter, down from their previous forecast of $2.15. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Leerink Partnrs also issued estimates for Danaher’s Q2 2026 earnings at $1.97 EPS.
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the business earned $1.72 earnings per share. The business’s revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS.
View Our Latest Analysis on Danaher
Danaher Price Performance
Shares of Danaher stock opened at $210.86 on Thursday. The stock’s 50-day simple moving average is $201.43 and its 200-day simple moving average is $197.23. Danaher has a 52 week low of $171.00 and a 52 week high of $279.41. The company has a market capitalization of $150.99 billion, a price-to-earnings ratio of 44.86, a PEG ratio of 2.94 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.
Danaher Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is presently 27.23%.
Insiders Place Their Bets
In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.10% of the stock is owned by insiders.
Institutional Investors Weigh In On Danaher
Several large investors have recently added to or reduced their stakes in DHR. GAMMA Investing LLC increased its stake in Danaher by 22.2% during the first quarter. GAMMA Investing LLC now owns 9,126 shares of the conglomerate’s stock worth $1,871,000 after acquiring an additional 1,660 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Danaher by 4.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 207,169 shares of the conglomerate’s stock valued at $42,470,000 after buying an additional 7,907 shares during the last quarter. Ritholtz Wealth Management grew its stake in shares of Danaher by 8.8% during the first quarter. Ritholtz Wealth Management now owns 6,469 shares of the conglomerate’s stock valued at $1,326,000 after buying an additional 522 shares during the last quarter. Sowell Financial Services LLC bought a new position in shares of Danaher during the first quarter valued at approximately $1,442,000. Finally, Sagespring Wealth Partners LLC grew its stake in shares of Danaher by 14.0% during the first quarter. Sagespring Wealth Partners LLC now owns 4,535 shares of the conglomerate’s stock valued at $930,000 after buying an additional 556 shares during the last quarter. 79.05% of the stock is owned by institutional investors.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- What Are Dividend Challengers?
- Salesforce’s Long-Awaited Inflection is Here: Rally On!
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Rocket Lab USA Receives Wall Street Validation: Time to Buy?
- How to find penny stocks to invest and trade
- Archer Buys Rival’s Patent Treasure Trove in Strategic Move
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.